|
gptkbp:instanceOf
|
gptkb:drug
antipsychotic medication
|
|
gptkbp:approvalYear
|
2015
|
|
gptkbp:approvedBy
|
gptkb:Canada
gptkb:Japan
gptkb:United_States
|
|
gptkbp:ATCCode
|
N05AX16
|
|
gptkbp:blackBoxWarning
|
suicidal thoughts and behaviors in children, adolescents, and young adults
increased mortality in elderly patients with dementia-related psychosis
|
|
gptkbp:brand
|
gptkb:Rexulti
|
|
gptkbp:CASNumber
|
913611-97-9
|
|
gptkbp:chemicalClass
|
quinolinone derivative
|
|
gptkbp:developedBy
|
gptkb:Otsuka_Pharmaceutical
gptkb:Lundbeck
|
|
gptkbp:eliminationHalfLife
|
91 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:form
|
gptkb:tablet
|
|
gptkbp:hasMolecularFormula
|
C25H27N3O2S
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Brexpiprazole
|
|
gptkbp:IUPACName
|
7-{4-[4-(1-benzothiophen-4-yl)piperazin-1-yl]butoxy}quinolin-2(1H)-one
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
antagonist at serotonin 5-HT2A receptor
partial agonist at dopamine D2 receptor
partial agonist at serotonin 5-HT1A receptor
|
|
gptkbp:metabolism
|
liver (CYP3A4, CYP2D6)
|
|
gptkbp:patent
|
gptkb:Otsuka_Pharmaceutical
gptkb:Lundbeck
|
|
gptkbp:pregnancyCategory
|
C
|
|
gptkbp:proteinBinding
|
99%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL2105728
11257422
9430467
DB09128
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
dizziness
headache
weight gain
insomnia
somnolence
akathisia
|
|
gptkbp:synonym
|
OPC-34712
|
|
gptkbp:UNII
|
K4M5RVW6FS
|
|
gptkbp:usedFor
|
gptkb:major_depressive_disorder
schizophrenia
|
|
gptkbp:bfsParent
|
gptkb:D08075
gptkb:D08170
|
|
gptkbp:bfsLayer
|
7
|